Positron Emission Tomography Imaging of Hypoxia

Area of Science:

• Nuclear medicine and molecular imaging.
• Oncology and preclinical research.
• Radiochemistry and radiopharmaceutical development.

Background:

• Hypoxia imaging is crucial for understanding ischemic events like stroke and myocardial ischemia.
• Tumor hypoxia significantly impacts treatment response and patient prognosis.
• Non-invasive imaging of hypoxia is essential for clinical applications.

Purpose of the Study:

• To review advancements in positron emission tomography (PET) imaging agents for hypoxia.
• To focus on the development and application of specific PET agents in hypoxia imaging.
• To provide an overview of current and emerging PET radiopharmaceuticals for hypoxia detection.

Main Methods:

• Review of existing literature on PET imaging agents for hypoxia.
• Focus on halogenated PET nitroimidazole agents labeled with Fluorine-18 ((18)F) and Iodine-124 ((124)I).
• Discussion of recently developed radiometal agents, specifically Copper-64-ATSM ((64)Cu-ATSM).

Main Results:

• Halogenated nitroimidazole PET agents have been investigated for over 25 years.
• Radiometal agents like (64)Cu-ATSM represent a more recent development in hypoxia imaging.
• These PET agents offer non-invasive methods for visualizing and quantifying hypoxia.

Conclusions:

• PET imaging agents are pivotal for non-invasive hypoxia assessment in various clinical scenarios.
• Continued development of novel PET agents will enhance diagnostic capabilities for hypoxic conditions.
• These imaging tools hold significant promise for improving patient outcomes in oncology and ischemic diseases.